Discover how our cutting-edge microflow-liquid chromatography and high-resolution mass spectrometry method reveals crucial species-specific differences in drug-to-antibody ratios of antibody-drug conjugates, offering new insights into their stability and efficacy across various biological matrices.

Explore our novel stapling strategy for enhancing the stability and reducing aggregation of bispecific antibodies through engineered disulfide bonds, showcased in our advanced workflow for optimizing and characterizing these critical disulfide linkages.

Discover the most effective strategies for quantifying post-translational modifications in therapeutic proteins, utilizing a hybrid approach with specific and non-specific enzyme digests, as revealed through our comprehensive assessment and advanced software solution, Byos.

Explore a streamlined middle-level approach for characterizing the fusion protein Blinatumomab, using targeted linker digestion and automated data analysis to simplify sample preparation and enhance fragment identification through advanced MS techniques.

Discover our innovative workflow for directly comparing LCMS and icIEF charge variant analysis, integrating icIEF fraction data with LC-MS data to enhance the characterization of monoclonal antibodies through a combined and automated approach.

Discover our novel Intact Reconstruction workflow for rapid characterization of bi-specific antibodies, effectively addressing challenges of mispairing chains, complex glycan profiles, and PTMs by integrating tryptic peptide data with intact mass spectrometry data.

Explore our innovative network-based method for building a sample-specific glycan database from MS/MS data, which discovered additional glycans and improved characterization of complex glycan structures, enhancing the accuracy and completeness of glycoprotein analysis.